Chemoprevention Strategies for Bladder Cancer
- DFMO (Difluoromethylornithin)
- Cyclooxygenase (COX)-2 selective inhibitors
The Benefits of Research
These agents are being evaluated in patients at high risk for tumor recurrence and progression, such as those with carcinoma in situ or high grade superficial bladder cancer. The ability to more accurately predict which patients with superficial bladder cancer will progress will also allow us to treat these patients more effectively. This research will hopefully enhance bladder-sparing approaches for treating bladder cancer, in which fewer patients with superficial bladder cancer will ultimately require radical cystectomy.
The UW Carbone Cancer Center has the resources to build a program in chemoprevention research, and as a tertiary referral center, many patients with genitourinary cancers such as bladder cancer may benefit from this research. It is our hope that these research efforts will lead to the prevention and early detection of bladder cancer, more accurate staging, appropriate patient selection for treatment, and more effective therapies.